Trial reportThe American journal of drug and alcohol abuse2009
Atomoxetine attenuates dextroamphetamine effects in humans.
Trial report in The American journal of drug and alcohol abuse, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.Journal of child and adolescent psychopharmacology · 2013Pooled it
- Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial.Drug and alcohol dependence · 2018Trial
- No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA.European journal of clinical pharmacology · 2018Trial
- Atomoxetine in abstinent cocaine users: Cognitive, subjective and cardiovascular effects.Pharmacology, biochemistry, and behavior · 2017Trial
- Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans.British journal of pharmacology · 2012Trial
- Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study.PloS one · 2012Trial
- Review
- Genotype-by-diagnosis interaction influences self-control in human cocaine addiction.Translational psychiatry · 2023Article
- The Supplement AdulterantThe Journal of pharmacology and experimental therapeutics · 2019Article
- 2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and αPsychopharmacology · 2019Article
- Reward-enhancing effect of methylphenidate is abolished in dopamine transporter knockout mice: A model of attention-deficit/hyperactivity disorder.Neuropsychopharmacology reports · 2018Article
- Atomoxetine in abstinent cocaine users: Sex differences.Data in brief · 2017Article
- Sex differences in reinstatement of cocaine-seeking with combination treatments of progesterone and atomoxetine.Pharmacology, biochemistry, and behavior · 2016Article
- Effects of the combination of wheel running and atomoxetine on cue- and cocaine-primed reinstatement in rats selected for high or low impulsivity.Psychopharmacology · 2015Article
- Pharmacological treatment of comorbid PTSD and substance use disorder: recent progress.Addictive behaviors · 2014Review
- Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.Pharmacology & therapeutics · 2012Review
- α- and β-Adrenergic receptors differentially modulate the emission of spontaneous and amphetamine-induced 50-kHz ultrasonic vocalizations in adult rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Article
- Physiological and subjective effects of acute intranasal methamphetamine during atomoxetine maintenance.Pharmacology, biochemistry, and behavior · 2011Article
- Monoamine transporters: vulnerable and vital doorkeepers.Progress in molecular biology and translational science · 2011Review
- Cognitive enhancement as a pharmacotherapy target for stimulant addiction.Addiction (Abingdon, England) · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundAlthough preclinical studies support the contribution of the noradrenergic system activation in mediating the acute effects of amphetamines, these findings have not been followed up in clinical studies.
objectivesTo examine the effects of atomoxetine, a norepinephrine transporter inhibitor, on subjective, physiological, and plasma cortisol responses to dextroamphetamine in 10 healthy volunteers.
methodsSubjects were randomly assigned to a sequence of atomoxetine (40 mg/day) or placebo treatments each lasting for 4 days. On Day 4 of each treatment period, responses to a single 20 mg/70 kg dose of dextroamphetamine were assessed.
resultsAtomoxetine treatment attenuated dextroamphetamine-induced increases in systolic and diastolic blood pressure and plasma cortisol as well as the self-report ratings of "stimulated," "high," and "good drug effects."
conclusionsThese findings are consistent with previous preclinical studies supporting the role of the noradrenergic system in mediating acute amphetamine responses. SCIENTIFIC SIGNIFICANCE: Atomoxetine's capacity to attenuate some of the physiological and subjective responses to dextroamphetamine supports its potential use for stimulant addiction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.